Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.57 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.57 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.52 |
| ▸ | NPY2R | P49146 | 5/20 | 0.52 |
| ▸ | NPY4R | P50391 | 5/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.52 |
| ▸ | NPY1R | P25929 | 3/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | EED | O75530 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30571140 | 0.91 | NPY2R (0.55) | MAPK8MAPK9MAPK10NPY2RNPY4R | |
| SCHEMBL29373861 | 0.91 | OPRD1 (0.62) | OPRD1OPRM1OPRK1 | |
| SCHEMBL30262211 | 0.89 | MAPK8 (0.60) | MAPK8MAPK9MAPK10OPRD1NPY2R | |
| SCHEMBL31711737 | 0.88 | MAPK8 (0.57) | MAPK8MAPK9MAPK10OPRD1NPY2R | |
| SCHEMBL30512723 | 0.88 | NPY2R (0.59) | MAPK8MAPK9MAPK10OPRD1NPY2R | |
| SCHEMBL29676363 | 0.88 | NTSR1 (0.57) | OPRD1OPRM1OPRK1 | |
| SCHEMBL30571125 | 0.88 | MAPK8 (0.56) | MAPK8MAPK9MAPK10NPY2RNPY4R | |
| SCHEMBL31281023 | 0.88 | MAPK8 (0.64) | MAPK8MAPK9MAPK10NPY2RNPY4R | |
| SCHEMBL31462347 | 0.87 | CALCR (0.56) | — | |
| SCHEMBL6232455 | 0.87 | NTSR2 (0.64) | MAPK8MAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136987-A1 | CHANNEL MODULATORS | INFLAMMX THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| CN-119462849-A | Polypeptide and application thereof in neurodegenerative diseases | 天津智泰生物医药科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| EP-4491184-A2 | CHANNEL MODULATORS | Auckland Uniservices Limited (NZ) | 2025-01-15 | — | — | EP | disclosed |
| EP-3183346-B1 | CHANNEL MODULATORS | AUCKLAND UNISERVICES LTD (NZ) | 2024-10-23 | — | — | EP | disclosed |
| US-20230174980-A1 | CHANNEL MODULATORS | INFLAMMX THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-11401516-B2 | Channel modulators | AUCKLAND UNISERVICES LIMITED (NZ) | 2022-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174980-A1 | CHANNEL MODULATORS | GJB2, GJA1, P2RX2 | MAPK8 2088/4885MAPK9 1519/4885MAPK10 1180/4885 |
| US-11401516-B2 | Channel modulators | GJB2, GJA1, P2RX2 | MAPK8 2088/4885MAPK9 1519/4885MAPK10 1180/4885 |
| US-20250136987-A1 | CHANNEL MODULATORS | GJB2, GJA1, P2RX2 | MAPK8 2088/4885MAPK9 1519/4885MAPK10 1180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.